Compugen, MedImmune set their sights on antibodies
HOLON, Israel—Compugen Ltd. and MedImmune, the global biologics research and development arm of AstraZeneca, have begun an exclusive license agreement aimed at developing bi-specific and multi-specific immuno-oncology antibody products, the companies announced in April. Per the agreement, MedImmune will receive an exclusive license to develop bi-specific and multi-specific antibody products derived from one of Compugen’s pipeline programs. The license grants MedImmune the right to develop multiple products, for which it will assume sole responsibility for all research, development and commercial activities. In return, MedImmune will pay Compugen $10 million up front, with the potential for up to $200 million in development, regulatory and commercial milestones for the first product, and tiered royalties on future product sales. Should additional products result from this deal, Compugen will be eligible for further milestones and royalties.